Molecular Diagnostics Partnering Universe Reviewed in New CurrentPartnering Research Report Available at MarketPublishers.com11 Apr 2016 • by Natalie Aster
LONDON – What are the exact rights granted or optioned? What is really granted by the molecular diagnostics agreement to the peer company? What type of exclusivity is granted? What is the payment structure associated with the deal? How are sales and payments audited? What are the terms of the contractual agreement? How are the major terms of the deal defined? How are intellectual property rights handled and owned? Who is in charge of commercialisation? Who holds responsibility for development, production, and supply? How are various disputes to be settled? Under which conditions can the agreement be terminated? What happens when ownership changes? Which boilerplate clauses does the firm insist on? Which boilerplate clauses appear to be different from deal type to deal type or partner to partner? All these and many more critical issues are addressed in the research publication.
New research study “Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts” drawn up by CurrentPartnering provides an in-depth understanding and access to molecular diagnostics deals landscape. It gives an overview of the trends and structure of deals entered into by the top life sciences companies since January 2010 from pole to pole. The study provides financial deal term values for the pertinent deals, listing by advance payments, headline value, intermediate payments and royalties, enabling to assess and benchmark the deals’ financial value. The report thoroughly examines the 25 leading dealmaker companies in the molecular diagnostics partnering universe, limelighting both the key deal values and most active dealmakers in the field, and thus disclosing those who blossom forth in this dynamic dealmaking marketplace. The manifold real life case studies of molecular diagnostics deals are included. The report offers unrivalled access to molecular diagnostics contract documents. Furthermore, more than 660 online deal records of actual molecular diagnostics deals are included and listed – by company A-Z, headline value, stage of development at signing, deal component type, specific therapy focus, and technology type.
Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts
Published: April, 2016
Price: US$ 2,995.00
More new studies by the publisher can be found at CurrentPartnering page.